Lymphopenia predicts disease severity of COVID-19: a descriptive and predictive study

Dear Editor, An outbreak of an unknown infectious pneumonia has recently occurred in Wuhan, China. The pathogen of the disease was quickly identified as a novel coronavirus (SARS-CoV-2, severe acute respiratory syndrome coronavirus 2), and the disease was named coronavirus disease-19 (COVID-19). The virus has so far caused 78,959 confirmed cases and 2791 deaths in China according to the reports of government. COVID-19 has been spreading in many countries such as Japan, Korea, Singapore, Iran, and Italia. The clinical manifestation of COVID-19 include fever, cough, fatigue, muscle pain, diarrhea, and pneumonia, which can develop to acute respiratory distress syndrome, metabolic acidosis, septic shock, coagulation dysfunction, and organ failure such as liver, kidney, and heart failure. Unfortunately, there is no effective medication other than comprehensive support. However, the mild type of COVID-19 patients can recover shortly after appropriate clinical intervention. The moderate type patients, especially the elderly or the ones with comorbidity, can worsen and became severe, indicating high mortality rate. However, efficient indicators for the disease severity, therapeutic response and disease outcome have not been fully investigated. Once such indicators are present, reasonable medication and care can be inclined, which is believed to significantly reduce the mortality rate of severe patients. Routine examinations include complete blood count, coagulation profile, and serum biochemical test (including renal and liver function, creatine kinase, lactate dehydrogenase, and electrolytes). Complete blood count is the most available, efficient and economic examination. This study aims to retrospect and analyze the timecourses of complete blood count of cured and dead patients, in order to obtain key indicators of disease progression and outcome and to provide guidance for subsequent clinical practice.

[1]  Charles Lee,et al.  COVID-19 preclinical models: human angiotensin-converting enzyme 2 transgenic mice , 2020, Human Genomics.

[2]  Yan Zhao,et al.  Clinical Characteristics of 138 Hospitalized Patients With 2019 Novel Coronavirus-Infected Pneumonia in Wuhan, China. , 2020, JAMA.

[3]  P. Camargos,et al.  What we know so far about Coronavirus Disease 2019 in children: A meta‐analysis of 551 laboratory‐confirmed cases , 2020, Pediatric pulmonology.

[4]  Y. Hu,et al.  Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China , 2020, The Lancet.

[5]  Taiwen Li,et al.  High expression of ACE2 receptor of 2019-nCoV on the epithelial cells of oral mucosa , 2020, International Journal of Oral Science.

[6]  Jiann-Jou Yang,et al.  IL-19 induces production of IL-6 and TNF-alpha and results in cell apoptosis through TNF-alpha. , 2002, Journal of immunology.

[7]  G. Gao,et al.  A Novel Coronavirus from Patients with Pneumonia in China, 2019 , 2020, The New England journal of medicine.

[8]  Gregor Rothe,et al.  Inhibitory effect of tumor cell-derived lactic acid on human T cells. , 2007, Blood.

[9]  Sasikanth Manne,et al.  Deep immune profiling of COVID-19 patients reveals patient heterogeneity and distinct immunotypes with implications for therapeutic interventions , 2020, bioRxiv.

[10]  P. Marik,et al.  A Descriptive Study , 2015 .

[11]  Jiann-Jou Yang,et al.  IL-19 Induces Production of IL-6 and TNF-α and Results in Cell Apoptosis Through TNF-α1 , 2002, The Journal of Immunology.

[12]  Ting Yu,et al.  Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study , 2020, The Lancet.

[13]  M. Merad,et al.  Immunology of COVID-19: Current State of the Science , 2020, Immunity.

[14]  K. Hashimoto,et al.  Poor-sleep is associated with slow recovery from lymphopenia and an increased need for ICU care in hospitalized patients with COVID-19: A retrospective cohort study , 2020, Brain, Behavior, and Immunity.